echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Merck met inhibitor "arresting" specific non-small cell lung cancer new gene "strangling" AML

    Merck met inhibitor "arresting" specific non-small cell lung cancer new gene "strangling" AML

    • Last Update: 2020-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    At the 20th World Lung Cancer Congress (wclc 2019), researchers published the latest data of keytruda (commonly known as K drug), a heavy-duty anti-PD-1 therapy developed by MSD company, in keynote-042 ChinaThe study was led by Professor Wu Yilong, vice president of Guangdong People's Hospital and director of Guangdong Lung Cancer Research InstituteThe results showed that, compared with the first-line treatment of advanced / metastatic non-small cell lung cancer (NSCLC) patients in China, the single drug therapy of pabolizumab can improve the OS of patients and has good safetyThis will add strength for pablizumab to join the first-line treatment of NSCLC in China< br / > pabolizumab, an anti-PD-1 therapy developed by mosadon, is a heavyweight drug in the field of immunosuppressive checkpoint inhibitorsBy inhibiting the immunosuppressive signal mediated by PD-1 receptor, T-lymphocytes in human body can be activated and attack tumor cellsAt present, the drug has been approved by the FDA of the United States to treat a variety of cancer types, but also approved in China for the treatment of non-small cell lung cancer and melanoma< br / > keynote-042 is an international, randomized, open label, three-phase study to compare the efficacy of pabolizumab and standard platinum chemotherapy in patients with locally advanced or metastatic PD-L1 positive (tumor ratio score TPS ≥ 1%) non-small cell lung cancerThese patients did not have EGFR or ALK mutations, and did not receive systemic treatment for advanced diseaseThe primary end point was to assess the overall survival (OS) of patients with TPS ≥ 50%, ≥ 20% and ≥ 1%The secondary end points were progression free survival (PFS) and objective response rate (ORR)< br / > the results showed that for PD-L1 TPS ≥ 50%, ≥ 20% and ≥ 1%, pablizumab improved OS compared with chemotherapyAmong the patients with TPS ranging from 1% to 49%, the improvement of total survival time by pablizumab was also better than that by chemotherapy (19.9 vs 10.7)In patients who received at least one dose of pabolizumab (n = 128) or chemotherapy (n = 125), the incidence of grade 3-5 drug-related adverse events (AE) was 17% and 68%, respectively< br / >< br / > target dementia related psychosis! Early termination of phase 3 clinical trials of Acadia innovative therapy < br / > Acadia pharmaceuticals, which focuses on the medical needs of central nervous system diseases, announced that its pimavanserin for the treatment of dementia related psychosis reached the main end point in the critical phase 3 trial harmonyAcadia plans to submit a new drug supplement application for pimavanserin by 2020Since there is no FDA approved drug for the treatment of dementia related psychosis, pimavanserin has the potential to become the first approved drug for this indication< br / > pimavanserin is a selective serotonin receptor Reverse agonist (ssiA), which can selectively target 5-HT2A receptor and reduce its basic activityIn humans, the activity of the 5-HT2A receptor is related to hallucinationsWhen it is stimulated by psychedelic drugs or other agonists, the central nervous system will produce psychedelic phenomena due to excitationHowever, the binding of pimavanserin to 5-HT2A receptor can weaken its activity, thus reducing the excitability of the central nervous system and the risk of hallucinations or delusionsIn 2016, the FDA approved the drug for marketing to treat hallucinations and delusions in Parkinson's patientsThe purpose of harmony was to verify the efficacy and safety of pimavanserin in relieving hallucinations or delusions in patients with different subtypes of dementia related psychosisDuring the 12 week open label stabilization period, patients who met the pre-defined remission criteria were randomly assigned to follow-up double-blind periods, or continue to receive pimavanserin, or switch to placeboThe primary end point of the trial was the time to relapse of dementia related psychosis during double blindnessThe mid-term efficacy analysis showed that pimavanserin significantly prolonged the duration of remission before relapse of dementia related psychosis compared with placebo, reaching the main end point of the trialBased on this result, Acadia company terminated this phase 3 clinical trial in advance< br / > AI helps drug discovery! Atomwise has entered into two collaborations < br / > atomwise, an artificial intelligence based drug design company, announced that it has created two joint ventures through cooperation with sengine precision medicine and oncostatyx, respectivelyIn cooperation with sengine precision medicine, the therapeutic effect of individualized drug molecules will be tested by using the in vivo tumor like organ model of cell culture obtained from patientsIn collaboration with oncostatyx, targeted inhibitors of three negative breast cancer-related proteins will be developed< br / > atomwise was founded in 2012Its core technology is atomnet, which is a virtual drug discovery platform technology based on deep learning neural network Like an anthropologist, atomnet uses powerful deep learning algorithms and computing power to analyze millions of potential new drug data Driven by a virtual brain, atomnet imitates the human visual cortex and trains itself by "learning" millions of data about the principle of drug action With this huge knowledge reserve, atomnet's virtual brain can use the patterns it perceives to predict the effectiveness of hypothetical drugs, and make some surprising suggestions for the use of existing drugs < br / > atomwise's AI technology can screen a large number of compounds, so as to identify and predict those chemical structures with high affinity, so that the development of drugs is no longer limited by the number of compounds and the resources needed to create and screen these compounds Through the AI platform to evaluate more molecules, researchers can find new treatment opportunities and new therapies After using the technology and collaborative workflow of atomwise, the drug discovery process that used to take years can theoretically be compressed to weeks or months < br / > photo source: atomwise official website < br / > the cooperation with sengine precision medicine aims to create a new cancer targeted therapy through "in vitro clinical trials" - that is, to screen hundreds of potential candidate drugs and drug combinations by using organ like organs derived from tumor cells of individual patients Sengine will provide gene targets related to cancer growth, and atomwise will use its AI program to develop personalized small molecule inhibitors, which will be tested in organ like models < br / > Add 800 million hearing loss patients! Frequency plans to raise another $100 million in IPO < br / > according to the World Health Organization (who), more than 800 million adults worldwide suffer from hearing loss Recently, frequency therapeutics, a cutting-edge company focusing on the use of human innate biology to repair or reverse hearing loss, submitted an IPO application to the US Securities and Exchange Commission to raise $100 million < br / > sensorineural hearing loss is the result of sensory hair cell damage and / or loss in the inner ear Once damaged, these inner ear hair cells will not regenerate spontaneously According to the National Institutes of health, about 90% of hearing loss patients are affected by sensorineural hearing loss It is understood that there is no approved treatment for sensorineural hearing loss Frequency's main research drug fx-322 aims to induce resting cells in inner ear to grow new hair cells, so as to restore hearing function < br / > ▲ frequency's technical method (picture source: sec) < br / > in the 1 / 2 phase clinical study of fx-322, frequency found that the patients' word recognition hearing function had a statistically significant improvement, and the patients' tolerance to the drug was good The company plans to start phase 2A clinical trials in the fourth quarter The study will recruit about 96 patients, with preliminary data expected in the second half of next year < br / > at present, frequency has reached a cooperation agreement with Astellas on the research of fx-322 According to the progress of drug development and commercialization, frequency will get up to $625 million < br / > arrest specific non-small cell lung cancer! German Merck met inhibitor has been recognized as a breakthrough therapy < br / > German Merck KGaA announced that the US FDA has granted its breakthrough therapy to treat patients with metastatic non-small cell lung cancer (NSCLC) carrying the jump mutation of met exon 14 These patients continue to deteriorate after receiving platinum based chemotherapy Prior to that, tepotinib had already obtained fast track qualification in Japan < br / > tepotinib is a highly selective oral met inhibitor developed by Merck in Germany It shows antitumor activity in NSCLC patients with overexpression or amplification of met In addition to being used in clinical trials for NSCLC patients, tepotinib is also used in phase 2 trials for HCC patients < br / > ▲ tepotinib molecular structure formula (picture source: PubChem) < br / > the breakthrough therapy is based on the ongoing phase 2 clinical study called vision A total of 73 patients with metastatic NSCLC confirmed by TBX or LBX were involved in the study Experimental data suggest that tepotinib may improve the treatment options of these patients For LBX confirmed patients, the overall response rate (ORR) of the Independent Review Committee (IRC) was 50%, and the investigator's result was 55.3% For patients confirmed by TBX, 45.1% and 54.9% respectively In terms of median duration of remission (DOR), IRC gave 12.4 months and 15.7 months for patients confirmed by LBX and TBX, respectively For these two groups of patients, the results were 17.1 months and 14.3 months, respectively < br / > Save hypoglycemia! Xeris ready to use glucagon injection has been approved by FDA < br / > xeris pharmaceuticals announced that FDA has approved the listing application of ready to use glucagon gvoke injection for the treatment of severe hypoglycemia Gvoke has two application devices: gvokepfs and gvokehypopen, which can be used in children over 2 years old and adults Xeris proprietary formula technology XeriSol Gamma And xeriject Gamma The super concentrated and low volume pastes were produced by using the non-aqueous polar solvent and the biocompatible diluent to "wet" the powder respectively Both small molecules and biomacromolecules (proteins, antibodies, vaccines) can be formulated with high stability and high solubility for intramuscular or subcutaneous injection The proprietary formulation technology of xeris overcomes the shortcomings of the traditional formulation, such as low stability (need to be refrigerated, need to be reconstructed with liquid diluent) and low solubility (need complex dissolution steps, need large injection dose), among which xeriject Gamma The solubility of biomacromolecules is more than 400 mg / ml, while the solubility range of traditional formula is 50 – 250 mg / ml < br / > Image Source: xeris provides < br / > FDA approval based on the results of three critical phase 3 trials These tests verify the efficacy, safety and practicability of gvoke in the treatment of type 1 diabetes mellitus induced hypoglycemia Gvoke was nearly 100% effective and successful in both children and adults < br / > hang AML! New gene innovative therapy significantly improves overall survival < br / > celgene announced that it is developing DNA methyltransferase inhibitor cc-486 as a maintenance therapy in a phase 3 trial for newly diagnosed patients with acute myeloid leukemia (AML)
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.